Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) have been given a consensus rating of “Buy” by the eight ratings firms that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $84.25.
ANIP has been the topic of a number of recent analyst reports. BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday. Zacks Investment Research raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, September 12th. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Guggenheim initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, September 12th. They set a “buy” rating and a $76.00 price target on the stock.
In related news, major shareholder Meridian Venture Partners Ii L sold 7,579 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $68.21, for a total value of $516,963.59. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 98,451 shares of company stock worth $7,006,801. 24.70% of the stock is owned by corporate insiders.
NASDAQ:ANIP opened at $72.69 on Tuesday. The company has a quick ratio of 0.74, a current ratio of 1.01 and a debt-to-equity ratio of 0.32. ANI Pharmaceuticals has a fifty-two week low of $36.92 and a fifty-two week high of $86.96. The stock has a market cap of $894.26 million, a PE ratio of 15.77 and a beta of 2.22. The firm’s fifty day simple moving average is $70.72 and its 200-day simple moving average is $71.91.
ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.18 by $0.26. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business had revenue of $54.36 million for the quarter, compared to analysts’ expectations of $55.20 million. During the same period in the prior year, the company posted $1.13 EPS. The business’s revenue for the quarter was up 15.0% on a year-over-year basis. Equities analysts anticipate that ANI Pharmaceuticals will post 5.29 earnings per share for the current year.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Further Reading: What causes a yield curve to invert?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.